DT&CRO CO., Ltd (383930) Fair Value & Analysis
Healthcare · KR · Market cap 34.4B KRW
Fair value as of: Jul 9, 2026
From 2 valuation models · updated today
Fair value updated Jul 9, 2026 — revised from 5,888 KRW to 1,315 KRW (−77.7%) since Jun 24, 2026. Share price −32.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 1,514 KRW – 4,201 KRW · fair‑value band 981.30 KRW – 1,963 KRW · the 1,810 KRW price screens above the 1,315 KRW fair value. As of Jul 9, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
DT&CRO CO., Ltd (383930) currently trades at 1,810 KRW, while our model-based Fair Value estimate is 1,315 KRW — implying the stock looks roughly 27.4% overvalued today. We read business quality at 25/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, DT&CRO CO., Ltd generated revenue of 47.8B KRW at a net margin of -25.7%. Revenue grew 0.2% year over year. It earns a return on equity of -68.8%. Net debt stands at 33.9B KRW. Fundamentals as of Jul 9, 2026
Our scenario range runs from 981.30 KRW (bear case) to 1,963 KRW (bull case); at 1,810 KRW, the current price sits within that range. The share trades about 56% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -27%, 383930 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 9, 2026. TTM = trailing twelve months.
About the company
DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
DT&CRO CO., Ltd reported revenue of 47.7B KRW in FY2025 versus 32.7B KRW in FY2021, a compound +9.9%/yr. Reported net income was −2.8B KRW in FY2025.
Is 383930 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 160,500 KRW | 76,943 KRW | -52% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is DT&CRO CO., Ltd (383930) undervalued?
What is the fair value of 383930?
What is the quality score of 383930?
What is the revenue of DT&CRO CO., Ltd (383930)?
What is the net profit margin of 383930?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.